Ultragenyx Pharmaceutical | RARE - Ebitda


Ultragenyx Pharmaceutical reported $-99.43M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Kyowa Hakko Kirin JPY 17.17B 28.58B Mar/2026
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xoma USD 2.52M 7.98M Jun/2024